The 82nd ADA meeting, June 3-7, 2022, hosted a debate surrounding targets for diabetes management being body weight or glycaemic control. Dr Osama Hamdy (Joslin Diabetes Center, Boston, MA, USA) discusses the array of phenotypes with which diabetes presents, with precision medicine being the ultimate goal.
Questions:Â
- What were your highlights of this year’s meeting? (0:23)
Disclosures: Osama Hamdy is a consultant for Abbott Nutrition and Sanofi Aventis, has received grant/research support from Eli Lilly, National Dairy Council and Novo-Nordisk. Osama Hamdy is on the advisory Board for L-Neutra, Nemaura and Twin Health and is a major stock shareholder in Healthimation Inc.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ADA 2022.
